rs267607123
Positions:
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 3P and 4B. PM1PP3BS2
The NM_003280.3(TNNC1):c.86T>A(p.Leu29Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000155 in 1,613,670 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000016 ( 0 hom. )
Consequence
TNNC1
NM_003280.3 missense
NM_003280.3 missense
Scores
2
6
11
Clinical Significance
Conservation
PhyloP100: 3.65
Genes affected
TNNC1 (HGNC:11943): (troponin C1, slow skeletal and cardiac type) Troponin is a central regulatory protein of striated muscle contraction, and together with tropomyosin, is located on the actin filament. Troponin consists of 3 subunits: TnI, which is the inhibitor of actomyosin ATPase; TnT, which contains the binding site for tropomyosin; and TnC, the protein encoded by this gene. The binding of calcium to TnC abolishes the inhibitory action of TnI, thus allowing the interaction of actin with myosin, the hydrolysis of ATP, and the generation of tension. Mutations in this gene are associated with cardiomyopathy dilated type 1Z. [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -1 ACMG points.
PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 7 uncertain in NM_003280.3
PP3
MetaRNN computational evidence supports a deleterious effect, 0.828
BS2
High AC in GnomAdExome4 at 24 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TNNC1 | NM_003280.3 | c.86T>A | p.Leu29Gln | missense_variant | 3/6 | ENST00000232975.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TNNC1 | ENST00000232975.8 | c.86T>A | p.Leu29Gln | missense_variant | 3/6 | 1 | NM_003280.3 | P1 | |
TNNC1 | ENST00000496590.1 | c.-47T>A | 5_prime_UTR_variant | 2/4 | 2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152202Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
1
AN:
152202
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251122Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135792
GnomAD3 exomes
AF:
AC:
1
AN:
251122
Hom.:
AF XY:
AC XY:
0
AN XY:
135792
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1461468Hom.: 0 Cov.: 31 AF XY: 0.0000206 AC XY: 15AN XY: 727044
GnomAD4 exome
AF:
AC:
24
AN:
1461468
Hom.:
Cov.:
31
AF XY:
AC XY:
15
AN XY:
727044
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152202Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74358
GnomAD4 genome
AF:
AC:
1
AN:
152202
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
74358
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 11, 2015 | The p.Leu29Gln variant in TNNC1 has been reported in 1 adult with HCM (Hoffmann 2001) and was absent from large population studies. Several vitro studies provid e conflicting data with some supporting a functional impact and others refuting this effect (Schmidtmann 2005, Baryshnikova 2008, Liang 2008, Dweck 2008, Neulen 2009, Parvatiyar 2012, Gollapudi 2012, Li 2013). Please note that in vitro assa ys may not accurately represent biological function. Leucine (Leu) at position 2 9 is conserved in mammals but not in evolutionarily distant species, and >10 fis h species carry a glutamine (Gln), raising the possibility that this change may be tolerated. In summary, due to the presence of conflicting data, the clinical significance of the p.Leu29Gln variant is uncertain. - |
Uncertain significance, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Oct 18, 2011 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p.Leu29Gln (c.86 T>A) in TNNC1 Of note, variants in TNNC1 are very rare and there is some debate about whether the strength of the evidence implicating this gene in cardiomyopathy. The variant has been seen in at least 1 unrelated case of HCM (not including this patient's family). No segregation data is available. The variant appears to be the first one reported in TNNC1 in association with HCM (Hoffmann et al 2001). I could not access the paper, however the following summary was provided in OMIM: "In a 60-year-old German man with hypertrophic cardiomyopathy (CMH13; 613243), Hoffmann et al. (2001) identified an 86T-A transversion in exon 3 of the TNNC1 gene, leading to a leu29-to-gln (L29Q) substitution at a conserved residue. No family members were available for study. The mutation was not detected in 96 controls, but the authors stated that they could not determine whether this was a disease-causing variant." In silico analysis with polyphen2 predicts this variant to be benign. In silico analysis with MutationTaster predicts the variant to be disease causing. The Leucine at codon is not completely conserved across species, and is in fact a glutamine in some species. Very few variants have been reported in association with disease in this gene, however at least one variant in a nearby codons (p.Ala31Ser (Parvatiyar et al 2012) has been reported with cardiomyopathy. Schmidtmann et al. (2005) studied the structural and functional consequences of this variant and observed only minor effects on secondary structure by circular dichroism (CD) spectroscopy. Schmidtmann et al. (2005) concluded that the variant hinders transduction of the phosphorylation signal from cardiac TnI to cardiac TnC. Liang et al. (2008) reported that the L29Q mutation enhances the Ca2??-binding characteristics of cTnC and that when incorporated into cardiac myocytes, this mutant alters myocyte contractility. Dweck et al. (2008) found that he lack of myofilament changes from L29Q-CTnC may preserve diastolic and systolic function, but is still indicative of the clinical outcome of HCM. Neulen et al. (2009) reported that this variant is unlikely to induce development of HCM by affecting regulation of Ca2+ activated force and interference with protein kinase A mediated modulation of Ca2+ sensitivity of contraction. In total the variant has not been seen in ~64,496 laboratory controls, published controls and individuals from publicly available population datasets. There is no variation at codon 29 listed in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/), which currently includes variant calls on ~64,000 individuals of European, African, Latino and Asian descent (as of January 21st, 2015, assuming same transcript, testing report doesn't provide transcript). The variant was not observed in the following laboratory and published control samples: 96 (Hoffmann et al 2001), 400 ethnically diverse controls studied by Familion/PGxHealth/Transgenomic. There is no variation at codon 29 listed in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/), which currently includes variant calls on ~64,000 individuals of European, African, Latino and Asian descent (as of January 21st, 2015, assuming same transcript, testing report doesn't provide transcript). - |
Dilated cardiomyopathy 1Z;C2750472:Hypertrophic cardiomyopathy 13 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 03, 2023 | This sequence change replaces leucine, which is neutral and non-polar, with glutamine, which is neutral and polar, at codon 29 of the TNNC1 protein (p.Leu29Gln). This variant is present in population databases (rs267607123, gnomAD 0.005%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 11385718). ClinVar contains an entry for this variant (Variation ID: 12442). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on TNNC1 function (PMID: 16302972, 18042489, 18063575, 18285522, 18820258, 19506933, 23008774, 23633581, 24260207, 26341255). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Clinical Exome/Genome Diagnostics Group, University Hospital Bonn | Mar 07, 2023 | - - |
Hypertrophic cardiomyopathy 13 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2005 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2017 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 19, 2024 | The p.L29Q variant (also known as c.86T>A), located in coding exon 3 of the TNNC1 gene, results from a T to A substitution at nucleotide position 86. The leucine at codon 29 is replaced by glutamine, an amino acid with dissimilar properties. This alteration has been reported in a hypertrophic cardiomyopathy (HCM) cohort (Hoffmann B et al. Hum Mutat, 2001 Jun;17:524). Several functional studies were performed for this alteration; however, they provided indeterminant results (Schmidtmann A et al. FEBS J, 2005 Dec;272:6087-97; Dweck D et al. J Biol Chem, 2008 Nov;283:33119-28; Liang B et al. Physiol Genomics, 2008 Apr;33:257-66; Neulen A et al. Basic Res Cardiol, 2009 Nov;104:751-60; Gollapudi SK et al. Biochem Res Int, 2012 Sep;2012:824068; Li AY et al. PLoS One, 2013 Nov;8:e79363; Stevens CM et al. J Biol Chem, 2017 Jul;292:11915-11926; Rayani K et al. FEBS J, 2022 Dec;289:7446-7465; Tikunova SB et al. Int J Mol Sci, 2023 Aug;24:[ePub ahead of print]). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Benign
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Benign
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
T
MutationAssessor
Benign
N
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Benign
T
Sift4G
Benign
T
Polyphen
B
Vest4
MutPred
Gain of catalytic residue at L29 (P = 0.0201);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: -2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at